Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Hypertension. 2016 Feb 29;67(5):927–933. doi: 10.1161/HYPERTENSIONAHA.115.07012

Figure 4.

Figure 4

Plasma (A) and urinary (B) angiotensinogen levels in transgenic Cyp1a1-Ren2 rats before (control, CO) and after treatment with indol-3-carbinol (I3C), with or without concomitant exposure to losartan (LOS) or hydralazine (HYD). *P<0.05 versus CO, and †P<0.05 versus I3C. Data are mean±SEM of n=4-5.